



Product	Potential Indications	Preclinical	Phase 1	Phase 2	Phase 3
 Aldafermin (NGM282) FGFR19 Analog	NASH				
 NGM313 (MK-3655) FGFR1c/KLB Agonistic Antibody	NASH, Type 2 Diabetes				
 NGM621 Complement C3 Inhibitory Antibody	Geographic Atrophy				
 NGM120 GFRAL Antagonistic Antibody	Cancer and Cancer Anorexia/ Cachexia Syndrome				
 NGM395 GDF15 Analog	Metabolic				